Paired box 3-Forkhead box protein O1 fusion protein (PAX3-FOXO1) (PAX3-FOXO1)

The PAX3-FOXO1 fusion protein is the pathognomonic driver of alveolar rhabdomyosarcoma (ARMS), a highly aggressive pediatric soft tissue sarcoma [PMID: 30232150]. This chimeric protein results from a t(2;13)(q35;q14) chromosomal translocation that fuses the DNA-binding domain of the Paired Box 3 (PAX3) transcription factor with the transactivation domain of the Forkhead Box O1 (FOXO1) protein [UniProt P23760]. PAX3-FOXO1 acts as a potent, constitutive transcriptional activator, significantly more active than wild-type PAX3, which leads to the dysregulation of genes involved in myogenesis, cell cycle control, and apoptosis [PMID: 28432221]. It effectively locks cells in a proliferative, undifferentiated state by activating pathways such as IGF1R, MET, and MYCN while suppressing terminal muscle differentiation [PMID: 25135934]. Although historically considered a difficult undruggable target, current research focuses on disrupting its transcriptional complex, promoting its degradation, or inhibiting downstream effectors and epigenetic regulators like HDACs and BET proteins [PMID: 31515458]. The presence of this fusion protein is a critical diagnostic and prognostic marker, typically associated with a more aggressive clinical course compared to fusion-negative rhabdomyosarcoma.

Other names

PAX3-FKHRt(2;13)(q35;q14) fusion proteinAlveolar rhabdomyosarcoma fusion proteinPAX3/FOXO1

The fusion protein functions as a chimeric transcription factor that constitutively activates the expression of genes promoting cell survival and proliferation while inhibiting muscle differentiation. Therapeutic strategies include the use of HDAC inhibitors to alter the epigenetic state of fusion-target genes, or the use of small molecules to disrupt the protein's transcriptional assembly [PMID: 31515458].